Oncolytics continues to push their pipeline further Print E-mail
By Patrick Crutcher   
Thursday, 02 December 2010 04:15

icon_newsnotesOncolytics Biotech Inc.(NASDAQ: ONCY) is another company pushing the limits of immunotherapeutics. Yesterday, they announced that enrollment had in a randomized Phase 2 ovarian cancer study using Reolysin. They currently have 11 ongoing studies.

This study will be a randomized phase 2 trial of weekly paclitaxel versus weekly paclitaxel with Reolysin in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H). They recently also began a Phase 1 trial in pediatric patients with relapsed or refractory solid tumors and announced some promising publications regarding their lead candidate, Reolysin.

Oncoloytics' Reolysin is an immunotherapy that works by using the reovirus to replicate in cancer cells that with a mutation known as an “activated Ras pathway,” but it spares normal cells; the reovirus then replicates in those cells with an active Ras signaling pathway, eventually killing the host cell and continuing this cycle. It has made some impressive results as a monotherapy, but has a particularly synergistic effect in combination with certain chemotherapeutics. 

With ONCY conducting eleven(11) clinical trials in the U.K. and U.S., it makes you wonder how they've done it without heavily diluting. This has only been possible thru collaborative agreements with the National Cancer Institute(NCI) in the U.S. to conduct multiple clinical trials, the Cancer Therapy and Research Center at the University of Texas Health Science Center has committed to funding up to five(5) Phase II clinical trials using Reolysin in combination with chemotherapy against a variety of advanced cancers, and sponsored studies in the UK. Oncolytics Biotech and clinical collaborators are actively testing Reolysin in ovarian cancer, colorectal cancer ( only patients with mutated Kras gene), melanoma, sarcoma, and pancreatic cancer.

Financially, these agreements have kept them afloat except for the occasional capital raise. More importantly, they are running a Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers that's being conducted under a Special Protocol Assessment(SPA). As we get close to top-line results later on down the road, you can be sure that volatility will increase. The Street and big pharma will be watching.

With a pipeline of 11 ongoing trials, we can expect ONCY to begin announcing results from these trials over the next 1-2 years. Note that they raised roughly $28 million back in early November and should have enough cash to see them through until 2012.  By then, we should have more complete knowledge on the potential for Reolysin.

Disclosure: No position.

ONCY begins Phase 2 in ovarian cancer - http://bit.ly/hsAHPA

Recent report on ONCY - http://biomedreports.com/2010112260394/oncolytic-viruses-are-they-the-future-of-cancer-therapy.html

Recent ONCY news - http://www.integratir.com/newsrelease.asp?ticker=t.onc

ONCY pipeline - http://www.oncolyticsbiotech.com/clinical.html




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter